Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7186-7191

  Schlienger, Nathalie ^a   Lund, Birgitte W ^a   Pawlas, Jan ^a   Badalassi, Fabrizio ^a   Bertozzi, Fabio ^a   Lewinsky, Rasmus ^a   Fejzic, Alma ^a   Thygesen, Mikkel B ^a   Tabatabaei, Ali ^b   Bradley, Stefania Risso ^b   Gardell, Luis R ^b   Piu, Fabrice ^b   Olsson, Roger ^a  

^a ACADIA Pharmaceuticals AB   (Sweden)

^b ACADIA PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 4 (3 ENDO HYDROXY 3 EXO METHYL 8 AZABICYCLO[3.2.1] OCT 8 YL) 3 METHYLBENZONITRILE; ACP 105; ANTIANDROGEN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASTRATED MALE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICROSOME; NONHUMAN; ORCHIECTOMY; PARTIAL AGONISM; PROSTATE CANCER; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; AZABICYCLO COMPOUNDS; DOGS; DRUG DESIGN; HUMANS; LIGANDS; MALE; MICE; MICROSOMES, LIVER; MUTATION; NIH 3T3 CELLS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RATS; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TESTOSTERONE PROPIONATE;

EID: 70949086681     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901149c     Document Type: Article

References (28)

1. (a) Gao, W.; Dalton, J. T. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discovery Today 2007, 12 (5-6), 241-248.
2. (b) Mohler, M. L.; Bohl, C. E.; Jones, A.; Coss, C. C.; Narayanan, R.; Dong, Y. E.; Hwang, J.; Dalton, J. T.; Miller, D. D. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J. Med. Chem. 2009, 52, 3597-3617.
3. (a) Nieschlag, E. Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinol. (Oxford) 2006, 65 (3), 275-281.
4. (b) Brueggemier, R. W.; Miller, D. D.; Witiak, D. T. Cholesterol, Adrenocorticoids, and Sex Hormones. In Principles of Medicinal-Chemistry, 4th ed.; Foye, W. O., Lemke, T. L., Williams, D. A., Eds.; Williams and Wilkins: Baltimore, MD, 1995; Chapter 23, pp 486-493.
5. (a) Basaria, S.; Dobs, A. S. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999, 15 (2), 131-142.
6. (b) Rhoden, E. L.; Morgentaler, A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. 2004, 350 (5), 482-492.
7. (c) Morgentaler, A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 2006, 50 (5), 935-939.
8. (d) Kicman, A. T. Pharmacology of anabolic steroids. Br. J. Pharmacol. 2008, 154 (3), 502-521.
9. (a) S-4: Marhefka, C. A.; Gao, W.; Chung, K.; Kim, J.; He, Y.; Yin, D.; Bohl, C.; Dalton, J. T.; Miller, D. D. Design, synthesis, and biological characterization of metabolically stable selective androgen receptor modulators. J. Med. Chem. 2004, 47 (4), 993-998.
10. (b) LGD2941: Martinborough, E.; Shen, Y.; Oeveren, A.; Long, Y. O.; Lau, T. L.; Marschke, K. B.; Chang, W. Y.; Lopez, F. J.; Vajda, E. G.; Rix, P. J.; Viveros, O. H.; Negro-Vilar, A.; Zhi, L. Substituted 6-(1-pyrrolidine)-quinolin- 2(1H)-ones as novel selective androgen receptor modulators. J. Med. Chem. 2007, 50 (21), 5049-5052.
11. BMS-564929: Ostrowski, J.; Kuhns, J. E.; Lupisella, J. A.; Manfredi, M. C.; Beehler, B. C.; Krystek, S. R., Jr.; Bi, Y.; Sun, C.; Seethala, R.; Golla, R.; Sleph, P. G.; Fura, A.; An, Y.; Kish, K. F.; Sack, J. S.; Mookhtiar, K. A.; Grover, G. J.; Hamann, L. G. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007, 148 (1), 4-12.
12. Heinlein, C. A; Chang, C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 2002, 23 (2), 175-200.
13. (a) Piu, F.; Gardell, L. R.; Son, T.; Schlienger, N.; Lund, B. W.; Schiffer, H. H.; Vanover, K. E.; Davis, R. E.; Olsson, R.; Bradley, S. R. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J. Steroid Biochem. Mol. Biol. 2008, 109 (1-2), 129-137.
14. (b) Acevedo, S.; Gardell, L.; Bradley, S. R.; Piu, F.; Raber, J. Selective androgen receptor modulators antagonize apolipoprotein E4-induced cognitive impairments. Lett. Drug Des. Discovery 2008, 5, 271-276.
15. Burstein, E. S.; Piu, F.; Ma, J. N.; Weissman, J. T.; Currier, E. A.; Nash, N. R.; Weiner, D. M.; Spalding, T. A.; Schiffer, H. H.; Del Tredici, A. L.; Brann, M. R. Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout. Curr. Pharm. Des. 2006, 12 (14), 1717-1729.
16. (a) Lund, B. W.; Piu, F.; Gauthier, N. K.; Eeg, A.; Currier, E.; Sherbukhin, V.; Brann, M. R.; Hacksell, U.; Olsson, R. Discovery of a potent, orally available, and isoform-selective retinoic acid β2 receptor agonist. J. Med. Chem. 2005, 48, 7517-7519.
17. (b) Piu, F.; Gauthier, N. K.; Olsson, R.; Currier, E. A.; Lund, B. W.; Croston, G. E.; Hacksell, U.; Brann, M. R. Identification of novel subtype selective RAR agonists. Biochem. Pharmacol. 2005, 71, 156-162.
18. (c) Seitzberg, J. G.; Knapp, A. E.; Lund, B. W.; Bertozzi, S. M.; Currier, E. A.; Ma, J.-N.; Sherbukhin, V.; Burstein, E. S.; Olsson, R. Discovery of potent and selective small-molecule PAR-2 agonists. J. Med. Chem. 2008, 51, 5490-5493.
19. (d) Lund, B. W.; Eeg, A.; Piu, F.; Gauthier, N. K.; Begtrup, M.; Hacksell, U.; Olsson, R. Design, synthesis and structure-activity analysis of isoform-selective retinoic acid β ligands. J. Med. Chem. 2009, 52, 1540-1545.
20. (e) Pettersson, H.; Bülow, A.; Ek, F.; Jensen, J.; Ottesen, L. K.; Fejzic, A.; Ma, J-.N.; Del Tredeci, A. L.; Currier, E. A.; Gardell, L. R.; Tabatabaei, A.; Craig, D.; McFarland, K.; Ott, T. R.; Piu, F.; Burstein, E. S.; Olsson, R. Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists. J. Med. Chem. 2009, 52, 1975-1982.
21. 3 LiCl) for the improved addition of organomagnesium reagents to carbonyl compounds. Angew. Chem., Int. Ed. 2006, 45, 497-500.
22. (b) The absolute configuration of this series of compounds was confirmed by crystal X-ray analysis of compound 9a, as a representative example for this series of compounds.
23. Sack, J. S.; Kish, K. F.; Wang, C.; Attar, R. M.; Kiefer, S. E.; An, Y.; Wu, J. E.; Scheffler, M. E.; Salvati, M. E.; Krystek, S. R., Jr.; Weinmann, R.; Einspahr, H. M. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (9), 4904-4909.
24. Ostrowski, J.; Kuhns, J. E.; Lupisella, J. A.; Manfredi, M. C.; Beehler, B. C.; Krystek, S. R., Jr.; Bi, Y.; Sun, C.; Seethala, R.; Golla, R.; Sleph, P. G.; Fura, A.; An, Y.; Kish, K. F.; Sack, J. S.; Mookhtiar, K. A.; Grover, G. J.; Hamann, L. G. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007, 148 (1), 4-12.
25. Bohl, C. E.; Wu, Z.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand induced conformational changes and structure-based drug design. J. Biol. Chem. 2007, 282 (18), 13648-13655.
26. (a) Gaddipati, J. P.; McLeod, D. G.; Heidenberg, H. B.; Sesterhenn, I. A.; Finger, M. J.; Moul, J. W.; Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 1994, 54, 2861-2864. (Pubitemid 24187763)
27. (b) Sun, C; Shi, Y; Xu, L. L.; Nageswararao, C.; Davis, L. D.; Segawa, T.; Dobi, A.; McLeod, D. G.; Srivastava, S. Androgen receptor mutation (T877A) promotes prostate cancer cellgrowth and cell survival. Oncogene 2006, 25, 3905-3913. (Pubitemid 43990745)
28. Full data of this study will be presented elsewhere.